A prospective, randomized study comparing cefozopran with piperacillin–tazobactam plus ceftazidime as empirical therapy for febrile neutropenia in children with hematological disorders
Authors:
- 9 October 2008
- journal article
- research article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 51 (6) , 774-777
Abstract
Background: The aim of this randomized study was to evaluate the efficacy of cefozopran monotherapy and piperacillin–tazobactam plus ceftazidime (PIPC/TAZ + CAZ) combination therapy in pediatric neutropenic patients.Procedure: A total of 51 patients with 138 episodes of febrile neutropenia received antibiotic therapy. Of these episodes, 95 were considered eligible for the study. The episodes were treated randomly with either piperacillin–tazobactam (125 mg/kg/day) plus ceftazidime (100 mg/kg/day) or with cefozopran (100 mg/kg/day). Success was defined as resolution of fever and clinical signs of infection within 120 hr following initiation of antibiotic therapy. Duration of neutropenia did not differ statistically between the two groups, and resolution of fever in all cases without complication was seen before recovery from severe neutropenia.Results: The overall success rate was 61%. There was no statistically significant difference between the two groups: 53% for PIPC/TAZ + CAZ versus 69% for cefozopran (P = 0.122). Blood cultures were positive in eight episodes (8.4%), but there were not deaths as a result of infection.Conclusion: Both cefozopran and PIPC/TAZ + CAZ combination therapy are safe and well tolerated in pediatric neutropenic patients. Our results show that cefozopran is a good candidate for monotherapy for neutropenic fever. Pediatr Blood Cancer 2008;51:774–777.Keywords
This publication has 18 references indexed in Scilit:
- Increasing Prevalence of Gastrointestinal Colonization With Ceftazidime-Resistant Gram-Negative Bacteria Among Intensive Care Unit PatientsInfection Control & Hospital Epidemiology, 2007
- Antimicrobial susceptibility of extended-spectrum β-lactamase producers and multidrug-resistant Acinetobacter baumannii throughout the United States and comparative in vitro activity of tigecycline, a new glycylcycline antimicrobialDiagnostic Microbiology and Infectious Disease, 2007
- Antimicrobial susceptibility pattern comparisons among intensive care unit and general ward Gram-negative isolates from the Meropenem Yearly Susceptibility Test Information Collection Program (USA)Diagnostic Microbiology and Infectious Disease, 2006
- Cefepime vs. Meropenem as empirical therapy for neutropenic fever in children with lymphoma and solid tumoursPediatric Blood & Cancer, 2003
- 2002 Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with CancerClinical Infectious Diseases, 2002
- A comparison of outcome from febrile neutropenic episodes in children compared with adults: results from four EORTC studiesBritish Journal of Haematology, 1997
- Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of CancerAntimicrobial Agents and Chemotherapy, 1995
- Monotherapy for fever and neutropenia in cancer patients: a randomized comparison of ceftazidime versus imipenem.Journal of Clinical Oncology, 1995
- Fever and granulocytopenia in children with cancer: A study of 299 episodes with two treatment protocols in BrazilMedical and Pediatric Oncology, 1993
- A Randomized Trial Comparing Ceftazidime Alone with Combination Antibiotic Therapy in Cancer Patients with Fever and NeutropeniaNew England Journal of Medicine, 1986